lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile

21 Pages Posted: 22 Jul 2020

See all articles by Jules Mesnier

Jules Mesnier

Department of Cardiology, Hôpital Bichat, AP-HP, Université de Paris, and FACT (French Alliance for Cardiovascular Trials)

Yves Cottin

Department of Cardiology, Hôpital du Bocage, EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté

Pierre Coste

Hôpital Cardiologique, Université de Bordeaux

Emile Ferrari

Department of Cardiology, Hôpital Pasteur, Université de Nice

Francois Schiele

Department of Cardiology, Hôpital Jean Minjoz, Université de Bourgogne-Franche-Comté

Gilles Lemesle

Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille

Christophe Thuaire

Department of Cardiology, Hôpital Louis Pasteur, CH de Chartres

Denis Angoulvant

Department of Cardiology, Hôpital Trousseau, CHRU de Tours & EA4245 T2i, Loire Valley Cardiovascular Collaboration, University of Tours

Guillaume Cayla

University of Montpellier - Department of Cardiology

Claire Bouleti

Université de Poitiers, CIC Inserm 1402, Department of Cardiology, Poitiers University Hospital

Romain Gallet de Saint Aurin

Department of Cardiology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris

Pascal Goube

South CH Francilien Corbeil Essonne

Thibault Lhermusier

Department of Cardiology, CHU Toulouse Rangueil

Jean-Guillaume Dillinger

Department of Cardiology, Hôpital Lariboisière, AP-HP, Université de Paris

Franck Paganelli

Department of Cardiology, Hôpital Nord

Anis Saib

Department of Cardiology,Groupe Hospitalier intercommunal le Raincy Montfermeil

Fabrice Prunier

nstitut MITOVASC, CNRS UMR 6015 INSERM U1083, Université d’Angers, Service de Cardiologie, CHU

Gerald Vanzetto

Urgences & Soins Intensifs Cardiologiques, LRB -INSERM 1039, CHU Grenoble Alpes

Olivier Dubreuil

Department of Cardiology, Centre Hospitalier St Joseph et St Luc

Etienne Puymirat

Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, and and FACT (French Alliance for Cardiovascular Trials)

Franck Boccara

AP-HP, Hôpitaux de l'Est Parisien, Hôpital Saint-Antoine, Department of Cardiology,Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine

Helene Eltchaninoff

National Institute of Health and Medical Research U644

Marine Cachanado

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Alexandra Rousseau

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Elodie Drouet

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Gabriel Steg

Department of Cardiology, Hôpital Bichat, AP-HP, Université de Paris, and FACT (French Alliance for Cardiovascular Trials)

Tabassome Simon

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Nicolas Danchin

University of Paris - Department of Cardiology

More...

Abstract

Aim: to evaluate the impact of a nationwide lockdown in France on acute myocardial infarction (AMI) admissions, by patient characteristics and regional prevalence of the pandemic.

Methods and Results: We collected data from 21 centres participating in the on-going FRENCHIE registry (NCT04050956), which collects data from all patients admitted for STEMI or NSTEMI within 48 hours of symptom onset. We compared weekly admissions in the 4 weeks preceding and the 4 weeks following institution of the lockdown. We observed a brutal 30% decrease in AMI admissions (24% for STEMI and 36% for NSTEMI, P=0.14) following institution of the lockdown, with similar trends according to gender (30% decrease in both men and women), risk factors, and regional prevalence of COVID-19. The decrease was numerically greater in patients aged 80 years or more (44% vs 27%, P=0.10). Patient characteristics, including time to hospital admission in STEMI patients, did not differ between the 2 periods. In-hospital mortality was numerically higher following institution of the lockdown (5.2% vs 3.4%, P=0.12), with similar trends for STEMI and NSTEMI.

Conclusion: A marked decrease in hospital admissions was observed following the lockdown, irrespective of patient characteristics and regional prevalence of COVID-19. Health authorities should be aware of these findings, in order to adapt their message in case of a second wave of the pandemic or future major epidemics.

Funding Statement: The FRENCHIE registry is supported by Recherche Hospitalo-universitaire en santé (RHU) iVasc within the programme "Investissements d'avenir", and sponsored by Assistance Publique – Hôpitaux de Paris (Délégation à la Recherche Clinique et à l'Innovation).

Declaration of Interests: YC reports research Grants to the Institution or Consulting/Lecture Fees from : Novartis , Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, outside the submitted work. P. Coste reports having received fees from Amgen, AstraZeneca, Bayer and Servier, outside the submitted work G. Lemesle reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BristolMyers Squibb, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier, and The Medicine Co, outside the submitted work. FS reports personal fees from Amgen, Astra Zeneca, Bayer, BMS, MSD, Pfizer, and Sanofi, outside the submitted work D. Angoulvant reports receiving consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Sanofi, Amgen, Novartis, Novo-Nordisk, Servier and MSD, outside the submitted work C. Bouleti reports receiving consulting and lecture fees from Novartis and AstraZeneca, outside the submitted work. G. Cayla has received research grants/consultant fees/lectures fees from Amgen, AstraZeneca, Abbott, Bayer, Biotronik, Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, outside the submitted work. P. Goube reports receiving consulting and lecture fees from AMGEN, SANOFI, BMS, ABBOT, outside the submitted work. T. Lhermusier has received research grants/consultant fees/lectures fees from AstraZeneca, Boston scientifics and Abbott, outside the submitted work A. Saib reports lectures fees from Novartis, outside the submitted work JG Dillinger reports receiving consulting and lecture fees from AstraZeneca, Bayer, BoehringerIngelheim, Bristol-Myers Squibb/Pfizer, Sanofi, and Daiichi-Sankyo and grants from Bayer, BristolMyers Squibb/Pfizer and Biosensors, outside the submitted work. F. Boccara reports research grants from Amgen; lecture fees from Janssen, Gilead, ViiV Healthcare, Amgen, Sanofi, MSD, and Servier outside the submitted work. And personal consultant or lecture fees from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Intercept, MSD, Novartis, Pfizer, Sanofi, and Servier, outside the submitted work. T. Simon reports grants from Astrazeneca, Daiichi-Sankyo, Eli-Lilly, GSK, MSD, Novartis, Sanofi, and personal fees for board membership and/or consultancy and/or lectures from AstraZeneca, BMS, Sanofi, and Novartis, outside the submitted work. N. Danchin has received research grants, or speaking and consulting fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Intercept, MSD, Novartis, Novo-Nordisk, Pfizer, Sanofi, Servier, outside the submitted work. The other authors have nothing to report.

Ethics Approval Statement: FRENCHIE has been approved by the Comité de Protection des Personnes and by the French data regulatory authority (Commission Nationale de l'Informatique et des Libertés).

Keywords: COVID-19; Acute myocardial infarction; epidemiology; trends

Suggested Citation

Mesnier, Jules and Cottin, Yves and Coste, Pierre and Ferrari, Emile and Schiele, Francois and Lemesle, Gilles and Thuaire, Christophe and Angoulvant, Denis and Cayla, Guillaume and Bouleti, Claire and de Saint Aurin, Romain Gallet and Goube, Pascal and Lhermusier, Thibault and Dillinger, Jean-Guillaume and Paganelli, Franck and Saib, Anis and Prunier, Fabrice and Vanzetto, Gerald and Dubreuil, Olivier and Puymirat, Etienne and Boccara, Franck and Eltchaninoff, Helene and Cachanado, Marine and Rousseau, Alexandra and Drouet, Elodie and Steg, Gabriel and Simon, Tabassome and Danchin, Nicolas, Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile (6/2/2020). Available at SSRN: https://ssrn.com/abstract=3619808 or http://dx.doi.org/10.2139/ssrn.3619808

Jules Mesnier

Department of Cardiology, Hôpital Bichat, AP-HP, Université de Paris, and FACT (French Alliance for Cardiovascular Trials)

Yves Cottin

Department of Cardiology, Hôpital du Bocage, EA 7460 Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne-Franche Comté

Pierre Coste

Hôpital Cardiologique, Université de Bordeaux

Emile Ferrari

Department of Cardiology, Hôpital Pasteur, Université de Nice

Francois Schiele

Department of Cardiology, Hôpital Jean Minjoz, Université de Bourgogne-Franche-Comté

Gilles Lemesle

Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille

Christophe Thuaire

Department of Cardiology, Hôpital Louis Pasteur, CH de Chartres

Denis Angoulvant

Department of Cardiology, Hôpital Trousseau, CHRU de Tours & EA4245 T2i, Loire Valley Cardiovascular Collaboration, University of Tours

Guillaume Cayla

University of Montpellier - Department of Cardiology

30029 Nîmes
France

Claire Bouleti

Université de Poitiers, CIC Inserm 1402, Department of Cardiology, Poitiers University Hospital

Romain Gallet De Saint Aurin

Department of Cardiology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris

Pascal Goube

South CH Francilien Corbeil Essonne

Corbeil Essonnes
France

Thibault Lhermusier

Department of Cardiology, CHU Toulouse Rangueil

Jean-Guillaume Dillinger

Department of Cardiology, Hôpital Lariboisière, AP-HP, Université de Paris

Franck Paganelli

Department of Cardiology, Hôpital Nord

Anis Saib

Department of Cardiology,Groupe Hospitalier intercommunal le Raincy Montfermeil

Fabrice Prunier

nstitut MITOVASC, CNRS UMR 6015 INSERM U1083, Université d’Angers, Service de Cardiologie, CHU

Gerald Vanzetto

Urgences & Soins Intensifs Cardiologiques, LRB -INSERM 1039, CHU Grenoble Alpes

Olivier Dubreuil

Department of Cardiology, Centre Hospitalier St Joseph et St Luc

Etienne Puymirat

Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, and and FACT (French Alliance for Cardiovascular Trials)

Franck Boccara

AP-HP, Hôpitaux de l'Est Parisien, Hôpital Saint-Antoine, Department of Cardiology,Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine

Helene Eltchaninoff

National Institute of Health and Medical Research U644

Rouen
France

Marine Cachanado

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Alexandra Rousseau

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Elodie Drouet

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Gabriel Steg

Department of Cardiology, Hôpital Bichat, AP-HP, Université de Paris, and FACT (French Alliance for Cardiovascular Trials)

Tabassome Simon

Department of Pharmacology and URCEST, Hôpital St Antoine, Université Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials)

Nicolas Danchin (Contact Author)

University of Paris - Department of Cardiology ( email )

Paris, 75015
France

Click here to go to TheLancet.com

Paper statistics

Abstract Views
123
Downloads
14